On May 23, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for the treatment of unresectable or metastatic solid tumors with the biomarker microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Read more
FDA approves cancer treatment for tumors with specific biomarker
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.